Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs... | Clinical Trial | StuddyBuddy@endsection Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05663827

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Conditions: Steroid Refractory GVHD

Sex: All
Ages: 3 Months – 30 Years
Phase: PHASE3
Enrollment: 6
Sponsor: Yi-Lun Wang

Location: Taiwan

Summary

Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We sought to evaluate the effect and safety of ruxolitinib (RUX) add-on in the treatment of patients with SR-GVHD.

Eligibility Criteria

Inclusion Criteria:Patients diagnosed with hematologic disorderExclusion Criteria:Those who are not applicable of receiving Ruxolitinib as immunodeficiency-modulation therapyThose who are actively encountering acute infectious illness

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05663827). StuddyBuddy aggregates publicly available trial information.